Effect on serum uric acid levels of drugs prescribed for indications other than treating hyperuricaemia

被引:102
作者
Daskalopoulou, SS
Tzovaras, V
Mikhailidis, DP
Elisaf, M [1 ]
机构
[1] Univ Ioannina, Sch Med, Dept Internal Med, GR-45110 Ioannina, Greece
[2] Univ London, Royal Free & Univ Coll Med Sch, Royal Free Hosp, Dept Clin Biochem, London, England
关键词
uric acid; urate; uricosuric; fenofibrate; losartan; NSAID; diuretic; atorvastatin;
D O I
10.2174/138161205774913309
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Beyond allopurinol and the well-established uricosuric drugs, several other agents can decrease serum uric acid (SUA) levels, such as losartan, fenofibrate and some non-steroidal anti-inflammatory drugs (NSAIDs). Some of these drugs increase renal urate excretion. Hyperuricaemia and gout are common problems (at least 1% of Western men are affected by gout). Raised SUA levels increase the incidence of acute gout and renal calculi. Hyperuricaemia may also predict an increased risk of vascular events. Therefore, lowering SUA levels is of clinical relevance. In this review we consider the effect on SUA levels of drugs that are prescribed for indications other than treating hyperuricaemia. These drugs may obviate the need for specific treatment (e.g. allopurinol) aimed at lowering SUA levels. Furthermore, because hyperuricaemic patients may already be on several drugs (e.g. due to associated dyslipidaemia, hypertension and/or arthritis) compliance may be improved by avoiding additional medication. The potential for adverse effects associated with polypharmacy would also be decreased.
引用
收藏
页码:4161 / 4175
页数:15
相关论文
共 285 条
[111]   THE URICOSURIC ACTION OF AZAPROPAZONE - DOSE-RESPONSE AND COMPARISON WITH PROBENECID [J].
HIGGENS, CS ;
SCOTT, JT .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1984, 18 (03) :439-443
[112]   The impact of serum uric acid on cardiovascular outcomes in the LIFE study [J].
Hoieggen, A ;
Alderman, MH ;
Kjeldsen, SE ;
Julius, S ;
Devereux, RB ;
de Faire, U ;
Fyhrquist, F ;
Ibsen, H ;
Kristianson, K ;
Lederballe-Pedersen, O ;
Lindholm, LH ;
Nieminen, MS ;
Omvik, P ;
Oparil, S ;
Wedel, H ;
Chen, C ;
Dahlöf, B .
KIDNEY INTERNATIONAL, 2004, 65 (03) :1041-1049
[113]  
HOMBERG JC, 1984, CLIN EXP IMMUNOL, V55, P561
[114]   USEFULNESS OF PIRETANIDE PLUS RAMIPRIL FOR SYSTEMIC HYPERTENSION - A MULTICENTER TRIAL [J].
HOMUTH, V ;
FAULHABER, HD ;
LOOSE, U ;
LOFFLER, K ;
LUFT, FC .
AMERICAN JOURNAL OF CARDIOLOGY, 1993, 72 (09) :666-671
[115]   RENAL EFFECTS OF ACUTE AND LONG-TERM TREATMENT WITH FELODIPINE IN ESSENTIAL-HYPERTENSION [J].
HULTHEN, UL ;
KATZMAN, PL .
JOURNAL OF HYPERTENSION, 1988, 6 (03) :231-237
[116]   EFFICACY AND MODE OF ACTION OF MANIDIPINE - A NEW CALCIUM-ANTAGONIST [J].
IIMURA, O ;
SHIMAMOTO, K .
AMERICAN HEART JOURNAL, 1993, 125 (02) :635-641
[117]   The effects of eprosartan, an angiotensin II AT1 receptor antagonist, on uric acid excretion in patients with mild to moderate essential hypertension [J].
Ilson, BE ;
Martin, DE ;
Boike, SC ;
Jorkasky, DK .
JOURNAL OF CLINICAL PHARMACOLOGY, 1998, 38 (05) :437-441
[118]   Effects of a low dose of indapamide, a diuretic, given daily or every-other-day on blood pressure and metabolic parameters [J].
Inaba, M ;
Noguchi, Y ;
Yamamoto, T ;
Imai, T ;
Hatano, M ;
Yagi, S ;
Katayama, S .
HYPERTENSION RESEARCH, 2004, 27 (03) :141-145
[119]   Correlates of uric acid and its association with asymptomatic carotid atherosclerosis: The ARIC Study [J].
Iribarren, C ;
Folsom, AR ;
Eckfeldt, JH ;
McGovern, PG ;
Nieto, FJ .
ANNALS OF EPIDEMIOLOGY, 1996, 6 (04) :331-340
[120]  
Isley William L, 2003, Expert Opin Drug Saf, V2, P581, DOI 10.1517/eods.2.6.581.21823